53. Li L, Yang J, Peng D, Zhang Y, Chen Y.177Lu-FAP-2286 therapy in a case of recurrent bladder cancer with multiple metastatic lesions. Clin Nucl Med. 2023;48:1012–1014. 54. Rao Z, Zhang Y, Liu L, Wang M...
53. Li L, Yang J, Peng D, Zhang Y, Chen Y. 177 Lu-FAP-2286 therapy in a case of recurrent bladder cancer with multiple metastatic lesions. Clin Nucl Med. 2023;48:1012–1014. 54. Rao Z, Zhang Y, Liu L, Wang M, Zhang C. [177Lu]Lu-FAP-2286 therapy in a case of right lun...
尽管FAPI PET在肿瘤预后判断中的相关研究样本数量较少、随访时间较短,随着病例的积累和对核素显像定量、半定量指标与临床资料进行详细解析,相信可以得到更多对临床有价值的信息。 FAP在多种癌症基质组织中过度表达,且经显像证实具有高肿瘤摄取、低本底摄取的特征,是...
尽管FAPI PET在肿瘤预后判断中的相关研究样本数量较少、随访时间较短,随着病例的积累和对核素显像定量、半定量指标与临床资料进行详细解析,相信可以得到更多对临床有价值的信息。 FAP在多种癌症基质组织中过度表达,且经显像证实具有高肿瘤摄取、低本底摄取的特征,是放射性配体治疗(targeted radioligand therapy, TRT)的优...
Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454–63. https://doi.org/10.1002/prca.201300095. Article CAS PubMed Google Scholar Liu R, Li H, Liu L, Yu J, Ren X. Fibroblast activation ...
FAP在多种癌症基质组织中过度表达,且经显像证实具有高肿瘤摄取、低本底摄取的特征,是放射性配体治疗(targeted radioligand therapy, TRT)的优越靶点。已有多项临床前研究和临床系列病例报道应用靶向FAP的抗体、肽类和小分子化合物进行TRT的初步探索。但是目前研究面临的一个重要问题是,这些FAPI分子存在快速被清除和在肿瘤...
FAP在多种癌症基质组织中过度表达,且经显像证实具有高肿瘤摄取、低本底摄取的特征,是放射性配体治疗(targeted radioligand therapy, TRT)的优越靶点。已有多项临床前研究和临床系列病例报道应用靶向FAP的抗体、肽类和小分子化合物进行TRT的初步探索。但是目前研究面临的一个重要问题是,这些FAPI分子存在快速被清除和在肿瘤...
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging [Internet]. 2022;49:3651–67. https://doi.org/10.1007/s00259-022-05842-5. Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K et al...
53. Li L, Yang J, Peng D, Zhang Y, Chen Y.177Lu-FAP-2286 therapy in a case of recurrent bladder cancer with multiple metastatic lesions. Clin Nucl Med. 2023;48:1012–1014. 54. Rao Z, Zhang Y, Liu L, Wang M...
Preclinical Evaluation of FAP-2286 for Fibroblast Activation Protein Targeted Radionuclide Imaging and Therapy. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 3651–3667. [Google Scholar] [CrossRef] Baum, R.P.; Schuchardt, C.; Singh, A.; Chantadisai, M.; Robiller, F.C.; Zhang, J.; ...